Clinical trial
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
NCT00017186 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00017186 |
|---|---|
| Title | Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma |
| Official title | Phase II Study of Gemcitabine and Epirubicin for the Treatment of Mesothelioma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Mesothelioma |
| Intervention type | Drug |
| Interventions | epirubicin hydrochloride, gemcitabine hydrochloride |
| Enrollment | 69 |
| Start date | Jul 1, 2001 |
| Primary completion | Aug 1, 2004 |
| Completion | May 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 7, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: